SCHEMBL1845113

SCHEMBL1845113

CCN1C(=O)Cc2c(C)nc(N3CCCCC3)nc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
HTT P42858 3/20 0.42
CYP1A2 P05177 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
POLB P06746 1/20 0.37
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.35
ATM Q13315 1/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 2/20 0.35
GBA1 P04062 1/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
PPP1CA P62136 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1847423 0.75 POLB (0.41) ALDH1A1HTTCYP1A2SMN1; SMN2POLB
SCHEMBL1847166 0.69 ALDH1A1 (0.43) ALDH1A1CYP1A2SMN1; SMN2CYP2C19HPGD
Hydrochloric Acid SCHEMBL8809398 0.68 ALDH1A1 (0.42) ALDH1A1CYP1A2SMN1; SMN2CYP2C19KDM4E
SCHEMBL28469771 0.67 MEN1 (0.58) ALDH1A1HTTSMN1; SMN2MEN1KMT2A
SCHEMBL1845316 0.65 POLB (0.39) ALDH1A1CYP1A2SMN1; SMN2POLBMEN1
SCHEMBL15246924 0.64 ALDH1A1 (0.52) ALDH1A1HTTCYP1A2SMN1; SMN2POLB
SCHEMBL15780901 0.63 ALDH1A1 (0.46) ALDH1A1HTTCYP1A2SMN1; SMN2POLB
SCHEMBL9686746 0.62 ALDH1A1 (0.43) ALDH1A1CYP1A2SMN1; SMN2MEN1KMT2A
SCHEMBL24359166 0.62 KDM4E (0.76) ALDH1A1HTTCYP1A2SMN1; SMN2KMT2A
SCHEMBL1707790 0.61 ALDH1A1 (0.49) ALDH1A1HTTCYP1A2SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324023-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2011-05-25 EP claimed
WO-2009070164-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2009-06-04 WO claimed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US claimed
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS Progenicyte Therapeutics, Inc. (US) 2023-09-28 US disclosed
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2021-02-18 US disclosed
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2019-06-06 US disclosed
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2018-04-05 US disclosed
EP-2326330-B1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIV CENTRAL FLORIDA RES FOUND (US) 2015-01-07 EP disclosed
US-8791128-B2 Compositions for treating or delaying the onset of hair loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-07-29 US disclosed
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2011-08-04 US disclosed
EP-2326330-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS University Of Central Florida Research Foundation, Inc. (US) 2011-06-01 EP disclosed
WO-2010087527-A1 ULTRAVIOLET ABSORBERS, AND PHARMACEUTICAL COMPOSITIONS AND COSMETICS CONTAINING PYRIMIDINE COMPOUNDS FOR UV PROTECTION AWAYA AKIRA (JP) 2010-08-05 WO disclosed
WO-2010033576-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-03-25 WO disclosed
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TREMBLEY MARCELLA 2009-04-02 US disclosed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 WO disclosed
US-5976523-A PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES MITSUI PHARMACEUTICALS, INC. (JP) 1999-11-02 US disclosed
EP-0743066-A2 Wound-healing agent MITSUI PHARMACEUTICALS, INC. (JP) 1996-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885HTT 1745/4885CYP1A2 800/4885
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885HTT 1745/4885CYP1A2 800/4885
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS PSEN1, PSEN2, NES ALDH1A1 4397/4885HTT 53/4885CYP1A2 4466/4885
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TYMP, TYMS, UNG ALDH1A1 1067/4885HTT 1130/4885CYP1A2 1110/4885
US-20110190320-A1 Compositions for Treating or Delaying the Onset of Hair Loss SHBG, CYP19A1, TYMP ALDH1A1 1649/4885HTT 3798/4885CYP1A2 1268/4885
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885HTT 1745/4885CYP1A2 800/4885
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS NES, PSEN1, PSEN2 ALDH1A1 2409/4885HTT 288/4885CYP1A2 4390/4885
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 ALDH1A1 318/4885HTT 1745/4885CYP1A2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.